Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets | Melis Akgün Canan et al. | ResearchPod

Transcript: Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets

Alex: Welcome to another episode of ResearchPod. Today, we're looking at how our bodies build the pancreas — specifically the cells that manage blood sugar.

Sam: We're discussing a study that challenges a long-standing assumption in biology. For decades, scientists believed human pancreas development worked the same way as it does in mice. This research suggests that human development follows a meaningfully different set of rules.

Alex: So this paper is essentially asking whether the "mouse manual" we've been using to grow human organs is actually correct?

Sam: Exactly. Researchers have been trying to grow insulin-producing cells in the lab to treat diabetes, but results have been inefficient. The prevailing model assumed two molecular switches — called ARX and PAX4 — compete against each other like rivals. This study indicates that in humans, it's not a competition at all. It's an orderly sequence.

Alex: That's a significant shift. If it's not a competition, how does the cell decide what to become?

Sam: Think of it like a relay race. In the mouse model, people assumed the two switches were fighting for control. In humans, PAX4 goes first — it starts the process — and then hands the baton to ARX, which locks in the final cell type. One initiates, the other confirms. It's a clean handoff, not a struggle.

Alex: So previous lab attempts were struggling because they were trying to recreate a competition that doesn't actually happen in human cells?

Sam: That's the core issue. To test this, the team engineered stem cells — the body's blank-slate starting cells — to glow with different colors depending on which switch was active. That let them watch the decision-making process unfold in real time, turning what had been a "black box" into something they could actually observe.

Alex: And by watching the colors change, they could see the relay race happening?

Sam: Precisely. They were mapping what you might call the cell's instruction manual — the chain of molecular signals that tells a cell what to become. Once they understood the correct sequence, they could use drugs to gently nudge cells along the right path, which the study suggests could improve how efficiently insulin-producing cells are grown for potential therapies.

Alex: That sounds promising. But does understanding the sequence mean we can now easily grow these cells for patients?

Sam: It's a meaningful step, but caution is warranted. This study clarifies the logic of how the cell makes its decision — but translating that into a reliable medical treatment is a separate and complex challenge. Think of it this way: we now have a more accurate map. But having the map and completing the journey are very different things.

Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets

Melis Akgün Canan, Corinna Cozzitorto, Michael Sterr, Lama Saber, Eunike S.A. Setyono, Xianming Wang, Juliane Merl-Pham, Tobias Greisle, Ingo Burtscher, Heiko Lickert

Jul 9, 2026·3:41·biorxiv·Original Paper

Cell fate allocationInduced pluripotent stem cells (iPSC)Gene regulatory network (GRN)Islet of LangerhansTranscription factorsDiabetes Mellitus

Listen

4 min

Briefing

Research Question and Approach

Understanding how pancreatic endocrine cells differentiate into glucagon-producing alpha cells or insulin-producing beta cells is critical for regenerative medicine in diabetes. Previous models, largely derived from mouse studies, suggested that the transcription factors ARX and PAX4 act as a binary switch, where they are co-expressed in early progenitors and cross-inhibit each other to dictate cell fate. To test if this model holds true in humans, the researchers generated a double-knock-in human induced pluripotent stem cell (hiPSC) reporter line (ARX-CFP; PAX4-mCherry) to track the spatiotemporal activity of these factors during in vitro differentiation.

Main Findings

By combining lineage tracing, single-cell multiomic analysis (snRNA-seq and snATAC-seq), and protein assays, the authors discovered that the mouse-based model of stochastic cross-inhibition does not apply to human development. Instead, they observed an asynchronous expression pattern: PAX4 is transiently active in early endocrine progenitors, whereas ARX activity emerges later, specifically in alpha cell progenitors. This suggests a sequential regulatory logic rather than a simultaneous competition. Furthermore, the study identified that pharmacological inhibition of FoxO1 enhances beta cell production, and the antimalarial drug artemether promotes endocrine induction and beta cell differentiation at the expense of alpha cells, providing new tools for optimizing stem cell-derived islet engineering.

Why It Matters

This research provides the first high-resolution map of human alpha versus beta cell fate segregation. By correcting the mechanistic understanding of how these cells are specified, the study enables more precise control over the differentiation of stem cells into functional islets. These findings are essential for improving cell-replacement therapies for type 1 diabetes and for developing more accurate human disease models for drug screening.

Key Terms and Definitions

ARX/PAX4 Reporter Line — A genetically engineered hiPSC line where fluorescent proteins (CFP and mCherry) are linked to the endogenous ARX and PAX4 genes, allowing real-time tracking of transcription factor activity.
Endocrine Progenitor (EP) — A multipotent cell stage in pancreatic development that gives rise to hormone-producing cells, including alpha, beta, delta, and epsilon cells.
Islet of Langerhans — The micro-organ in the pancreas responsible for blood glucose control, containing clusters of hormone-producing cells.
Multiomic Analysis — An integrated approach combining single-nucleus RNA sequencing and ATAC sequencing to simultaneously analyze gene expression and chromatin accessibility in individual cells.
Transdifferentiation — The process by which one mature cell type converts into another, often investigated as a potential mechanism for regenerating insulin-producing beta cells.

Abstract

Abstract Stem cell-derived glucagon-(α) and insulin-producing (β) cells allow to engineer in vitro biomimetics of islet of Langerhans, the micro-organ controlling glycemia; however, a knowledge gap in the mechanism by which human stem cell-derived α and β cells are specified persists. Mouse studies postulated that Aristaless Related homeobox (Arx) and Paired box 4 (Pax4) transcription factors cross-inhibit each other in endocrine progenitors to promote α/β fate allocation, respectively. To test this model in human, we combine lineage labelling with single-cell multiomic analysis in our newly generated ARX CFP/CFP ; PAX4 mCherry/mCherry knock-in induced pluripotent stem cell reporter line. Lineage tracing, proteomic and gene regulatory network analysis and potency assays reveal a human specific regulation of α/β cell fate allocation. Pharmacological perturbations previously proposed to trigger α-to-β transdifferentiation or identified by our gene regulatory network lead to enhanced endocrine induction and directed α/β cell fate. Studying mechanisms of endocrinogenesis and fate segregation enables the engineering of islets in vitro, and has broader implications for cell-replacement therapy, disease modelling and drug screening.

Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets: Research Paper Podcast